

DAFTAR PUSTAKA

- Afroz, A., Alam, K., Ali, L., Karim, A., Alramadan, M.J., Habib, S.H., dkk., 2019. Type 2 diabetes mellitus in Bangladesh: a prevalence based cost-of-illness study. *BMC health services research*, **19**: 1–12.
- Afroz, A., Alramadan, M.J., Hossain, M.N., Romero, L., Alam, K., Magliano, D.J., dkk., 2018. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review. *BMC health services research*, **18**: 972.
- Al-Attab, A.K.T. dan Al-Lami, M.Q.D., 2019. Effects of duration and complications of type 2 diabetes mellitus on diabetic related parameters, adipocytokines and calcium regulating hormones. *Iraqi Journal of Science*, **60**: 2353–2361.
- Alwayesh, M.S., Aljunid, S.M., Al-Adsani, A., Alessa, T., Alattar, A., dan Alroudhani, D., 2022. Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait. *PloS one*, **17**: 1–15.
- Alzarea, A.I., Khan, Y.H., Alanazi, A.S., Butt, M.H., Almalki, Z.S., Alahmari, A.K., dkk., 2022. Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries. *International Journal of Environmental Research and Public Health*, **19**: .
- An, J., Nichols, G.A., Qian, L., Munis, M.A., Harrison, T.N., Li, Z., dkk., 2021. Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes. *BMJ Open Diabetes Research and Care*, **9**: 1–10.
- Anders, H.J., Huber, T.B., Isermann, B., dan Schiffer, M., 2018. CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease. *Nature Reviews Nephrology*, **14**: 361–377.
- Ashri, R., Aulia, D., dan Siregar, F.A., 2023. Analysis of Medical Costs of Type 2 Diabetes Mellitus Outpatient Muhammadiyah Hospital North Sumatra. *Jurnal Medicoeticolegal dan Manajemen Rumah Sakit*, **12**: 188–195.
- Bala, C., Rusu, A., Ciobanu, D., dan Roman, G., 2022. Length of Hospital Stay, Hospitalization Costs, and Their Drivers in Adults with Diabetes in the Romanian Public Hospital System. *International journal of environmental research and public health*, **19**: 1–13.
- Baroroh, F., Solikah, W.Y., dan Urfiyya, Q. 'Aina, 2016. Analisis Biaya terapi Diabetes Melitus Tipe 2 Di Rumah Sakit PKU Muhammadiyah Bantul Yogyakarta. *Jurnal Farmasi Sains dan Praktis*, **1**: 11–22.
- Barthold, D., Li, J., dan Basu, A., 2024. Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare **7**: 1–12.
- Bina Pelayanan Kefarmasian, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Bootman, J.L., Townsend, R.J., dan McGhan, W.F., 2005. *Principles of Pharmacoeconomics*. Harvey Whitney Books Company, United States of America.
- Braithwaite, S.S., Clark, L.P., Idrees, T., Qureshi, F., dan Soetan, O.T., 2018. Hypoglycemia Prevention by Algorithm Design During Intravenous Insulin

- Infusion. *Current Diabetes Reports*, **18**: 1–14.
- Brazier, J., Ara, R., Azzabi, I., Busschbach, J., Chevrou-Séverac, H., Crawford, B., dkk., 2019. Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. *Value in Health*, **22**: 267–275.
- Butt, M.D., Ong, S.C., Wahab, M.U., Rasool, M.F., Saleem, F., Hashmi, A., dkk., 2022. Cost of Illness Analysis of Type 2 Diabetes Mellitus: The Findings from a Lower-Middle Income Country. *International Journal of Environmental Research and Public Health*, **19**: 1–15.
- Chen, C., Song, J., Xu, X., Zhou, L., Wang, Y., dan Chen, H., 2020. Analysis of influencing factors of economic burden and medical service utilization of diabetic patients in China. *PLoS ONE*, **15**: 1–14.
- Ciarambino, T., Crispino, P., Leto, G., Mastrolorenzo, E., Para, O., dan Giordano, M., 2022. Influence of Gender in Diabetes Mellitus and Its Complication. *International Journal of Molecular Sciences*, **23**: 1–13.
- Cole, J.B. dan Florez, J.C., 2020. Genetics of diabetes mellitus and diabetes complications. *Nature Reviews Nephrology*, **16**: 377–390.
- De Ferranti, S.D., De Boer, I.H., Fonseca, V., Fox, C.S., Golden, S.H., Lavie, C.J., dkk., 2014. Type 1 diabetes mellitus and cardiovascular disease a scientific statement from the american heart association and american diabetes association. *Circulation*, **130**: 1110–1130.
- De Franco, E., Flanagan, S.E., Houghton, J.A.L., Allen, H.L., MacKay, D.J.G., Temple, I.K., dkk., 2015. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: An international cohort study. *The Lancet*, **386**: 957–963.
- Diabetes Care, 2021. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetesd2021. *Diabetes Care*, **44**: 111–124.
- Dipiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., dan Ellingrod, V., 2020. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. McGraw Hill, Washington.
- Domeikienė, A., Vaivadaite, J., Ivanauskienė, R., dan Padaiga, Ž., 2014. ScienceDirect Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania. *MEDICINA*, **50**: 54–60.
- Elsayed, N.A., Aleppo, G., Aroda, V.R., Bannuru, R.R., Brown, F.M., Bruemmer, D., dkk., 2023. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2023. *Diabetes Care*, **46**: 267–278.
- Feldman, E.L., Callaghan, B.C., Pop-Busui, R., Zochodne, D.W., Wright, D.E., Bennett, D.L., dkk., 2019. Diabetic neuropathy. *Nature Reviews Disease Primers*, **5**: .
- Fong, H.K., Desai, R., Faisaluddin, M., Parekh, T., Mahmood, A., Shah, V., dkk., 2021. Sex disparities in cardiovascular disease outcomes among geriatric patients with prediabetes. *Primary Care Diabetes*, **15**: 95–100.
- Guariguata, L., Whiting, D.R., Hambleton, I., dan Beagley, J., 2014. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Research and Clinical Practice*, **103**: 137–149.
- Haidar, S., Vazquez, R., dan Medic, G., 2023. Impact of surgical complications on

- hospital costs and revenues: retrospective database study of Medicare claims. *Journal of Comparative Effectiveness Research*, **12**: 1–17.
- Hartanto, D. dan Mulyani, T., 2017. Gambaran Biaya Pasien Diabetes Melitus Tipe 2 Dengan Terapi Antidiabetik Oral Di RSUD Ulin Banjarmasin. *Jurnal Ilmiah Ibnu Sina*, **2**: 109–116.
- Hayul, H., Andayani, T.M., dan Oetari, 2020. Analisis Kesesuaian Biaya Riil Terhadap Penetapan Tarif Ina-Cbg'S Pasien Nefropati Diabetik Rawat Inap Di Rsud Ir.Soekarno Sukoharjo Tahun 2018. *Jurnal Farmasi & Sains Indonesia*, **3**: 26–36.
- Hidayat, B., Ramadani, R.V., Rudijanto, A., Soewondo, P., Suastika, K., Yi, J., dkk., 2022. Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia. *Value in Health Regional Issues*, **28**: 82–89.
- Hulst, A.H., Polderman, J.A.W., Siegelaar, S.E., van Raalte, D.H., DeVries, J.H., Preckel, B., dkk., 2021. Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. *British Journal of Anaesthesia*, **126**: 567–571.
- İçağasıoğlu, A., Baklacioğlu, H.Ş., Mesci, E., Yumuşakhuylu, Y., Murat, S., dan Mesci, N., 2017. Economic burden of stroke Afitap. *Turk J Phys Med Rehab*, **63**: 155–159.
- International Diabetes Federation, 2021. *Diabetes Atlas, 10th Edition*, 10th ed. Brussels, Belgium.
- Jalmav, M.M.A. dan Yuniati Hoiriyah, Y., 2021. Cost Analysis Terapi Antidiabetik pada In Patient Diabetes Melitus Tipe 2 di RSU Anwar Medika. *Jurnal Farmasi Indonesia*, **13**: 202–209.
- Kansra, P. dan Oberoi, S., 2023. Cost of diabetes and its complications: results from a STEPS survey in Punjab, India. *Global Health Research and Policy*, **8**: 1–11.
- Kementerian Kesehatan Republik Indonesia, 2018. *Hasil Utama Riset Kesehatan Dasar 2018*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian kesehatan Republik Indonesia, 2020. *Kinerja Pembangunan Kesehatan Di Indonesia : Tantangan , Masalah , Dan Solusi*. Badan Penelitian dan Pengembangan Kesehatan, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2023. *Profil Kesehatan Indonesia 2022*. Kementerian Kesehatan Republik Indonesia, jakarta.
- Kim, D.D., Silver, M.C., Kunst, N., Cohen, J.T., Ollendorf, D.A., dan Neumann, P.J., 2020. Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. *Pharmacoeconomics*, **38**: 1135–1145.
- Klein-Schwartz, W., Stassinis, G.L., dan Isbister, G.K., 2015. Treatment of sulfonylurea and insulin overdose. *British Journal of Clinical Pharmacology*, **81**: 496–504.
- Kolb, H., Kempf, K., dan Martin, S., 2023. Insulin and aging – a disappointing relationship. *Frontiers in Endocrinology*, **14**: 1–10.
- Larg, A. dan Moss, J.R., 2011. Cost of Illness Studies. *Pharmacoeconomics*, **29**: 653–71.
- Lemeshow, S., 1997. *Besar Sampel Dalam Penelitian Kesehatan*. Gajah Mada

University Press, Yogyakarta.

- Li, X., Xu, Z., Ji, L., Guo, L., Liu, J., Feng, K., dkk., 2019. Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study. *Journal of diabetes investigation*, **10**: 539–551.
- Lo, Z.J., Surendra, N.K., Saxena, A., dan Car, J., 2021. Clinical and economic burden of diabetic foot ulcers: A 5-year longitudinal multi-ethnic cohort study from the tropics. *International wound journal*, **18**: 375–386.
- Martínez-Castelao, A., Navarro-González, J.F., Luis Górriz, J., dan De Alvaro, F., 2015. The concept and the epidemiology of diabetic nephropathy have changed in recent years. *Journal of Clinical Medicine*, **4**: 1207–1216.
- Mata-Cases, M., Casajuana, M., Franch-Nadal, J., Casellas, A., Castell, C., Vinagre, I., dkk., 2015. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. *The European journal of health economics*, **17**: 1001–1010.
- Menteri Kesehatan Republik Indonesia, 2014. *Peraturan Menteri Kesehatan Republik Indonesia Nomor 27 Tahun 2014 Tentang Petunjuk Teknis Sistem Indonesian Case Base Groups (INA-CBG)*, Menteri Kesehatan Republik Indonesia. Jakarta.
- Menteri Kesehatan Republik Indonesia, 2023. *Peraturan Menteri Kesehatan Republik Indonesia Nomor 3 Tahun 2023 Tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan Program Jaminan Kesehatan*. Jakarta.
- Moon, J.H. dan Jang, H.C., 2022. Gestational Diabetes Mellitus: Diagnostic Approaches and Maternal-Offspring Complications. *Diabetes and Metabolism Journal*, **46**: 3–14.
- Murphy, E.M., Rodis, J.L., dan Mann, H.J., 2020. Three ways to advocate for the economic value of the pharmacist in health care. *Journal of the American Pharmacists Association*, **60**: .
- Mutyambizi, C., Pavlova, M., Chola, L., Hongoro, C., dan Groot, W., 2018. Cost of diabetes mellitus in Africa: a systematic review of existing literature. *Globalization and health*, **14**: 1–13.
- Naseri, M.W., Esmat, H.A., dan Bahee, M.D., 2022. Prevalence of hypertension in Type-2 diabetes mellitus. *Annals of Medicine and Surgery*, **78**: 1–4.
- National Team for the Acceleration of Poverty Reduction, 2015. *The Road to National Health Insurance (JKN)*. National Team for the Acceleration of Poverty Reduction, Jakarta.
- Ng, C.S., Paul, M., Sim, H., Ko, Y., dan Lee, J.Y., 2015. Direct Medical Cost of Type 2 Diabetes in Singapore. *PLOS ONE*, 1–11.
- Oktadiana, I., 2021. Perbandingan Biaya Riil Pada Pasien Diabetes Mellitus Tipe 2 Dengan Tarif INA-CBG ' S Di Rumah Sakit Umum Daerah. *Jurnal Farmasi Tinctura*, **2**: 42–51.
- Onukwugha, E., McRae, J., Kravetz, A., Varga, S., Khairnar, R., dan Mullins, C.D., 2016. Cost-of-Illness Studies: An Updated Review of Current Methods. *Pharmacoeconomics*, **34**: 43–58.
- Oyando, R., Njoroge, M., Nguhiu, P., Sigilai, A., Kirui, F., Mbui, J., dkk., 2020. Patient costs of diabetes mellitus care in public health care facilities in Kenya.

- John Wiley & Sons Ltd*, **35**: 290–308.
- Parry, H.M., Deshmukh, H., Daniel Levin, Zuydam, N. Van, Elder, D.H.J., Morris, A.D., dkk., 2015. Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. *Circulation: Heart Failure*, **8**: 236–242.
- Patty, Y.F.P.P., Mufarrihah, dan Nita, Y., 2021. Cost of illness of diabetes mellitus in Indonesia: A systematic review. *Journal of Basic and Clinical Physiology and Pharmacology*, **32**: 285–295.
- PERKENI, 2021. *Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2021*. PERKENI.
- Petersmann, A., Müller-Wieland, D., Müller, U.A., Landgraf, R., Nauck, M., Freckmann, G., dkk., 2019. Definition , Classification and Diagnosis of Diabetes Mellitus. *German Diabetes Association: Clinical Practice Guidelines*, **127**: 1–7.
- Pham, H.T.K., Kieu, T.T.M., Duong, T.D., Nguyen, K.D. Van, Tran, N.Q., Tran, T.H., dkk., 2020. Direct medical costs of diabetes and its complications in Vietnam : A national health insurance database study. *Diabetes Research and Clinical Practice*, **162**: 1–8.
- Pinchevsky, Y., Butkow, N., Raal, F.J., Chirwa, T., dan Rothberg, A., 2020. Demographic and clinical factors associated with development of type 2 diabetes: A review of the literature. *International Journal of General Medicine*, **13**: 121–129.
- Pop-Busui, R., Boulton, A.J.M., Feldman, E.L., Bril, V., Freeman, R., Malik, R.A., dkk., 2017. Diabetic neuropathy: A position statement by the American diabetes association. *Diabetes Care*, **40**: 136–154.
- Pratiwi, A. dan Sukmawati, H., 2019. Analisis Biaya Rata-Rata Pasien Rawat Inap Dengan Penyakit Diabetes Mellitus Tipe II (Studi Di Jembrana Dan Gianyar). *Jurnal Lingkungan & Pembangunan*, Oktober 2019, **3**: 21–29.
- Przezak, A., Bielka, W., dan Pawlik, A., 2022. Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities. *International Journal of Molecular Sciences*, **23**: 1–16.
- Putri, R.E.K., Darmawan, E., dan Perwitasari, D.A., 2019. Cost of Illness Diabetes Melitus Tipe 2 dan Komplikasinya pada Peserta Jaminan Kesehatan Nasional (JKN) di Rawat Jalan Rumah Sakit Condong Catur Yogyakarta Cost of Illness Type 2 Diabetes Mellitus and Its Complications in National Health Insurance at Ou. *Pharmacon: Jurnal Farmasi Indonesia*, **16**: 89–101.
- Quaye, E.A., Amporful, E.O., Akweongo, P., dan Aikins, M.K., 2015. Analysis of the Financial Cost of Diabetes Mellitus in Four Cocoa Clinics of Ghana. *Value in Health Regional Issues*, **7**: 49–53.
- Rascati, K.L., 2014. *Essentials of Pharmacoeconomics*, second edi. ed, Angewandte Chemie International Edition, 6(11), 951–952. Lippincott Williams & Wilkins, Texas.
- Sanchez-Rangel, E. dan Inzucchi, S.E., 2017. Metformin: clinical use in type 2 diabetes. *Diabetologia*, **60**: 1586–1593.
- Sasongko, M.B., Wardhana, F.S., Febryanto, G.A., Agni, A.N., Supanji, S., Indrayanti, S.R., dkk., 2019. The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025. *British Journal of*

Ophthalmology, **104**: 487–492.

- Sauenram, N., Sillabutra, J., Viwatwongkasem, C., dan Satitvipawee, P., 2023. Estimation of the onset time of diabetic complications in type 2 diabetes patients in Thailand: a survival analysis. *Osong Public Health and Research Perspectives*, **14**: 508–519.
- Shuvo, S. Das, Hossen, M.T., Riazuddin, M., Hossain, M.S., Mazumdar, S., Parvin, R., dkk., 2023. Prevalence of comorbidities and its associated factors among type-2 diabetes patients: a hospital-based study in Jashore District, Bangladesh. *BMJ open*, **13**: e076261.
- Sivaprasad, S., Gupta, B., Crosby-Nwaobi, R., dan Evans, J., 2012. Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide Perspective. *Survey of Ophthalmology*, **57**: 347–370.
- Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Jaime Caro, J., Lee, K.M., Minchin, M., dkk., 2014. Budget impact analysis - Principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force. *Value in Health*, **17**: 5–14.
- Tandah, M.R., Janna, R.R., Mallisa, T., dan Diana, K., 2024. Analisis Biaya Medis Langsung Dan Tarif Ina-Cbg's Pasien Diabetes Melitus Tidak Tergantung Insulin Di RSUD Anutapura Palu. *Jurnal Ilmiah Ibnu Sina*, **8**: 57–70.
- Tonin, F.S., Aznar-Lou, I., Pontinha, V.M., Pontarolo, R., dan Fernandez-Llimos, F., 2021. Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. *Pharmacy Practice*, **19**: 1–10.
- Valkovicova, T., Skopkova, M., Stanik, J., dan Gasperikova, D., 2019. Novel insights into genetics and clinics of the HNF1A-MODY. *Endocrine Regulations*, **53**: 110–134.
- Wang, J., Zuo, H., Chen, X., Hou, L., dan Ma, J., 2019. Analysis of factors influencing the frequency of primary care visits among diabetic patients in two provinces in China. *BMC public health*, **19**: 1–8.
- Williams, J.S. dan Egede, L.E., 2020. Differences in Medical Expenditures for Men and Women with Diabetes. *Women's Health Reports*, **1**: 345–353.
- Wu, H., Eggleston, K.N., Zhong, J., Hu, R., Wang, C., Xie, K., dkk., 2018. How do type 2 diabetes mellitus (T2DM)-related complications and socioeconomic factors impact direct medical costs? A cross-sectional study in rural Southeast China. *BMJ open*, **8**: e020647.
- Xia, M., Liu, K., Feng, J., Zheng, Z., dan Xie, X., 2021. Prevalence and Risk Factors of Type 2 Diabetes and Prediabetes Among 53, 288 Middle-Aged and Elderly Adults in China : A Cross-Sectional Study. *Dovepress*, **14**: 1975–1985.
- Yao, J., Wang, H., Yan, J., Shao, D., Sun, Q., dan Yin, X., 2021. Understanding the profiles of blood glucose monitoring among patients with type 2 diabetes mellitus: A cross-sectional study in Shandong, China. *Patient Preference and Adherence*, **15**: 399–409.
- Yuniarti, E., Handayani, T.M., Manajemen, M., Universitas, F., dan Mada, G., 2015. Analisis Biaya Terapi Penyakit Diabetes Melitus Pasien Jaminan Kesehatan Nasional; di RS PKU Muhammadiyah Yogyakarta-Perbandingan Terhadap Tarif INA-CBG. *Jurnal Kebijakan Kesehatan Indonesia*, **04**: 97–103.

- Zaidi, S.T.R. dan Babar, Z.U.D., 2015. Applying Pharmacoeconomics in Community and Hospital Pharmacy Research. *Pharmacy Practice Research Methods*, 1–247.
- Zhuo, X., Zhang, P., dan Hoerger, T.J., 2013. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. *American Journal of Preventive Medicine*, **45**: 253–261.